skip to content

Contract Wins and Joint Ventures

Oxford BioMedica to lead £2m gene therapy collaboration project

11 August 2017 09:08

Oxford BioMedica has agreed, as lead partner, to enter into a collaboration agreement with a consortium of partners for a two-year £2 million project focused on gene and cell therapy manufacturing, co-funded by Innovate UK.

The aim of the collaboration is to explore and apply novel advanced technologies to further evolve OXB's proprietary suspension LentiVector platform to deliver higher quality vectors for both clinical and commercial use.

The project aims to shorten the time-to-clinic and time-to-market as well as to improve the cost and access of bringing novel gene and cell therapies to patients.

John Dawson, chief executive officer of Oxford BioMedica, said: "Cell and gene therapies offer unprecedented promise for the cure, treatment or long term management of disease and we are delighted that this consortium has been awarded funding from Innovate UK that will help to keep Oxford BioMedica, our partners and the UK, at the forefront of innovation in industrial viral vector manufacturing."

At 9:08am: (LON:OXB) Oxford BioMedica PLC share price was -0.37p at 8.93p

Story provided by

Related Company: OXB

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.